Androgen Replacement Therapy in Turner Syndrome: A Pilot Study

Zuckerman‐Levin, Nehama; Frolova-Bishara, Tatiana; Militianu, Daniela; Levin, Moshe; Aharon‐Peretz, Judith; Hochberg, Zèev

doi:10.1210/jc.2009-0514

Cited by 59 publications

(37 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found a small reduction of HDL cholesterol in the Ox-treated groups. This is in line with a recent study on the use of methyltestosterone in adult women with TS, although in that study the decrease in HDL during treatment was accompanied by a reduction of total cholesterol and triglycerides resulting in a more favorable lipid profile (32). Also in the US study, the decrease in HDL was accompanied by a decrease in triglycerides (8).…”

Section: Discussionsupporting

confidence: 87%

See 1 more Smart Citation

Long-term effects of previous oxandrolone treatment in adult women with Turner syndrome

Freriks

Sas

Traas

et al. 2013

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Short stature is a prominent feature of Turner syndrome (TS), which is partially overcome by GH treatment. We have previously reported the results of a trial on the effect of oxandrolone (Ox) in girls with TS. Ox in a dose of 0.03 mg/kg per day (Ox 0.03) significantly increased adult height gain, whereas Ox mg/kg per day (0.06) did not, at the cost of deceleration of breast development and mild virilization. The aim of this follow-up study in adult participants of the pediatric trial was to investigate the long-term effects of previous Ox treatment. Design and methods: During the previous randomized controlled trial, 133 girls were treated with GH combined with placebo (Pl), Ox 0.03, or Ox 0.06 from 8 years of age and estrogen from 12 years. Sixtyeight women (Pl, nZ23; Ox 0.03, nZ27; and Ox 0.06, nZ18) participated in the double-blind followup study (mean age, 24.0 years; mean time since stopping GH, 8.7 years; and mean time of Ox/Pl use, 4.9 years). We assessed height, body proportions, breast size, virilization, and body composition. Results: Height gain (final minus predicted adult height) was maintained at follow-up (Ox 0.03 10.2 G4.9 cm, Ox 0.06 9.7G4.4 cm vs Pl 8.0G4.6 cm). Breast size, Tanner breast stage, and body composition were not different between groups. Ox-treated women reported more subjective virilization and had a lower voice frequency. Conclusion: Ox 0.03 mg/kg per day has a beneficial effect on adult height gain in TS patients. Despite previously reported deceleration of breast development during Ox 0.03 treatment, adult breast size is not affected. Mild virilization persists in only a small minority of patients. The long-term evaluation indicates that Ox 0.03 treatment is effective and safe.European Journal of Endocrinology 168 91-99

show abstract

Section: Discussionsupporting

confidence: 87%

“…In general, women with TS tend to have an increase in BMI and fat mass including visceral fat (29,30,31). In a pilot study in adult women with TS, androgen treatment increased lean body mass and decreased fat mass (32). In our pediatric study, we also showed a reduction in fat mass and an increment in muscle mass during Ox treatment (15).…”

Section: Discussionsupporting

confidence: 51%

Long-term effects of previous oxandrolone treatment in adult women with Turner syndrome

Freriks

Sas

Traas

et al. 2013

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…They should have access to a gynecologist experienced in ovarian insufficiency in young women. Improved sexual function may require additional topical estrogen per vaginum or systemic androgen supplements, but so far, there is little information on their use in women with TS (455,456).…”

Section: Sexual Function In Adultsmentioning

confidence: 99%

Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting

Gravholt¹,

Andersen

Conway

et al. 2017

European Journal of Endocrinology

825

1,259

View full text Add to dashboard Cite

Turner syndrome affects 25-50 per 100,000 females and can involve multiple organs through all stages of life, necessitating multidisciplinary approach to care. Previous guidelines have highlighted this, but numerous important advances have been noted recently. These advances cover all specialty fields involved in the care of girls and women with TS. This paper is based on an international effort that started with exploratory meetings in 2014 in both Europe and the USA, and culminated with a Consensus Meeting held in Cincinnati, Ohio, USA in July 2016. Prior to this meeting, five groups each addressed important areas in TS care: 1) diagnostic and genetic issues, 2) growth and development during childhood and adolescence, 3) congenital and acquired cardiovascular disease, 4) transition and adult care, and 5) other comorbidities and neurocognitive issues. These groups produced proposals for the present guidelines. Additionally, four pertinent questions were submitted for formal GRADE (Grading of Recommendations, Assessment, Development and Evaluation) evaluation with a separate systematic review of the literature. These four questions related to the efficacy and most optimal treatment of short stature, infertility, hypertension, and hormonal replacement therapy. The guidelines project was initiated by the European Society of Endocrinology and the Pediatric Endocrine Society, in collaboration with the European Society for Paediatric Endocrinology, the Endocrine Society, the European Society of Human Reproduction and Embryology, the American Heart Association, the Society for Endocrinology, and the European Society of Cardiology. The guideline has been formally endorsed by the European Society of Endocrinology, the Pediatric Endocrine Society, the European Society for Paediatric Endocrinology, the European Society of Human Reproduction and Embryology and Summary of recommendationsThe recommendations (R) are worded as recommend (strong recommendation) and suggest (weak recommendation). We formally graded only the evidence underlying recommendations for therapeutic choices. The quality of evidence behind the recommendations is classified as very low (⨁◯◯◯), low (⨁⨁◯◯), moderate (⨁⨁⨁◯) and strong (⨁⨁⨁⨁). See further section 'Summary of methods used for guideline development'. Diagnosis and geneticsR 1.1. We recommend considering a diagnosis of TS in phenotypic females with a karyotype containing one X chromosome and complete or partial absence of the second sex chromosome, associated with one or more typical clinical manifestations of TS (⨁⨁⨁⨁). R 1.2. We recommend against considering a diagnosis of TS in females with one X chromosome and a deletion distal to Xq24 on the other X chromosome, and in women over the age of 50 years with less than 5% 45,X mosaicism (⨁⨁◯◯). R 1.3. We suggest that the new general surveillance management guideline applies to TS patients with any karyotype (⨁⨁◯◯). R 1.4. We recommend to consider testing for Turner syndrome (TS) in a female with typical signs (Table 2) (⨁⨁⨁⨁). R 1.5. We ...

show abstract

“…Zuckerman-Levin and cols. have shown that the administration of methyl-testosterone had improved the lipid profile, not only with a reduction in total cholesterol, LDL cholesterol and triglycerides, but also with a decrease in HDL cholesterol (44). However, Wilson and cols.…”

Section: Cardiovascular Riskmentioning

confidence: 94%

Endocrine diseases, perspectives and care in Turner syndrome

Collett‐Solberg

Gallicchio

Coelho

et al. 2011

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

SUMMARYTurner syndrome is a frequent chromosome disorder in clinical practice. It is characterized by short stature, gonadal dysgenesia and multisystemic involvement, responsible for a high morbidity and reduced life expectancy. The aim of the present paper is to describe the endocrinopathies and major problems at different ages, and to present suggestion for follow-up care in these patients. Arq Bras Endocrinol Metab. 2011;55(8):550-8

show abstract

Androgen Replacement Therapy in Turner Syndrome: A Pilot Study

Abstract: Androgen insufficiency plays a role in TS-impaired body composition, neurocognition, and QOL, and these aspects improve with ART, which was safe and effective when given for 1 yr.

Cited by 59 publications

References 52 publications

Long-term effects of previous oxandrolone treatment in adult women with Turner syndrome

Long-term effects of previous oxandrolone treatment in adult women with Turner syndrome

Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting

Endocrine diseases, perspectives and care in Turner syndrome

Contact Info

Product

Resources

About